Fabry disease revisited: Management and treatment recommendations for adult patients

Alberto Ortiz, Dominique P. Germain, Robert J. Desnick, Juan Politei, Michael Mauer, Alessandro Burlina, Christine Eng, Robert J. Hopkin, Dawn Laney, Aleš Linhart, Stephen Waldek, Eric Wallace, Frank Weidemann, William R. Wilcox

Research output: Contribution to journalReview article

67 Scopus citations


Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the “classic” phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.

Original languageEnglish (US)
Pages (from-to)416-427
Number of pages12
JournalMolecular Genetics and Metabolism
Issue number4
StatePublished - Apr 2018


  • Diagnosis
  • Fabry disease
  • Management
  • Mutation
  • Treatment

Fingerprint Dive into the research topics of 'Fabry disease revisited: Management and treatment recommendations for adult patients'. Together they form a unique fingerprint.

  • Cite this

    Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., Waldek, S., Wallace, E., Weidemann, F., & Wilcox, W. R. (2018). Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 123(4), 416-427. https://doi.org/10.1016/j.ymgme.2018.02.014